Assessing the social value of novel regimens for MDR TB

Location

Baltimore, Maryland, US

Dates

07/01/2014 - 06/01/2015

PI

David Dowdy, MD, PhD, ScM

We are collaborating with investigators from the Berman Bioethics Institute to develop novel techniques for economic evaluation that also incorporate considerations of social value, using novel regimens for MDR-TB as a paradigmatic example.

Projects

A Blueprint for Success: Understanding the...

We are using a combination of statistical analysis and transmission modeling, in collaboration with the NYC Dept of Health &...

Read More

Quantitative assessment of the tipping point...

Quantitative methods will be used to study Mtb dynamics to determine the tipping point for macrophage infection, which depends...

Read More

Population-level impact of isoniazid...

We are collaborating with a team that conducted a randomized trial of IPT in Khayelitsha, South Africa, to extend their findings...

Read More